Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer

Maurizio Scaltriti(Harvard University), José Baselga(Harvard University)
Molecular Cancer Therapeutics
March 8, 2011
Cited by 52


Related Papers